Member Info for EmeraldCarrots

Coming up with say £15 million is not that much these days. I could priobably come up with £200k for starters.

NHS hospital departments in the UK. A sitting asleep duck for a takeover. The tech is valuable too in the USA where the Genedrive® MT-RNR1 is unique. Get FDA clearance for that and you have a license to print money. What is wrong with investors for heavens sake!!!!!!!!! It's all staring you in the face. Are you blind?? This situation is compeltely mad. Beyond mad. No word for it.

All IMHO.

---BID!---. The sp is now totally and utterly insane. I'd accept 5p a share I think.

--RNS--. Market cap just £9.3m sp should get re-rated on this news. Neonatal, Stroke and now Cardiovascular in play for the UK's NHS.

So for what £20m (say 3p a share, current sp x 2) a big pharma might be able to buy Genedrive. Really. That is ridiculous IMHO. They would say they have offered TWICE the market cap. Makes a lot of sense does it not???????????????????????????? Offering double what the market values Genedive at!!!!!

In addition to stroke for the CYP2C19-ID. Already have Neonatal for the Genedrive® MT-RNR1 (and potentially not only babies but adults too). Now Cardiovascular in addition to stroke for the CYP2C19-ID . These 3 represent a market that is massive. Indeed how would Genedrive cope!! The market should re-rate this share............ Back to 3p? The current sp is mad low IMHO.

https://www.lse.co.uk/rns/GDR/cyp2c19-id-kit-used-to-support-expansion-glxxcub28eo0bmk.html

Neonatal for the Genedrive® MT-RNR1 (and potentially not only babies but adults too). Now Cardiovascular in addition to stroke for the CYP2C19-ID . These 3 represent a market that is massive. Indeed how would Genedrive cope!! The market should re-rate this share............ Back to 3p?

All IMHO.

View of the consumables being.............. consumed! 14 hospitals will be using the Genedrive® MT-RNR1 soon also............

-------rapid point of care CYP2C19 testing in cardiovascular disease-----.

"Integration of this rapid test into routine practice means we can get patients on the right treatment the first time, improving outcomes for our patients and the service as a whole.""

Guy_incognito

"Well at least that’ll fund this week".

================================

Hello,

-------rapid point of care CYP2C19 testing in cardiovascular disease-----.

This is much more than the order money. It's a whole new use for the CYP2C19 machine. "over 100,000 hospital admissions each year due to heart attacks, with these patients often requiring lifelong antiplatelet therapy.". Again might be rolled out throughout the NHS.........

Excellent new news.

Cancer is still in its infancy, but detecting cancer is getting better:-

"Last month, it was announced the NHS would trial the ‘miONCO-Dx’ test with 8,000 patients."

https://www.dailymail.co.uk/health/article-14694059/blood-tests-detect-earliest-signs-cancer-prevent-advanced-stage.html

Looked it up on A.I. to see where we are with actually targeting a cancer with drugs in the same way. Long way to go on that score by the looks. One wonders if once the cancer is indicated by this ‘miONCO-Dx’ test Angle's dual analysis could be used? The dual analysis can find twice the number of biomarkers that CtDna analysis can alone. The ‘miONCO-Dx’ test could find the cancer, then Angle’s dual analysis could find the DNA biomarkers that existing cancer drugs can target. Food for thought!

===================================================

miRNA-Targeted Drugs:-

Challenges and Future Directions:

Delivery:

Delivering miRNA-based drugs to the tumor site efficiently and safely is a major challenge.

Toxicity:

Some miRNA-based drugs have shown adverse effects in clinical trials, highlighting the need for further research and development.

Immune Response:

miRNA-based drugs can trigger immune responses, which need to be carefully considered and managed.

Clinical Translation:

Despite promising preclinical studies and clinical trials, none of these miRNA-based drugs have reached phase 3 trials or been approved by the FDA to date.

Despite these challenges, miRNA-targeted therapies hold great promise for the future of cancer treatment. Ongoing research and development efforts are focused on overcoming the existing limitations and improving the safety and efficacy of these innovative drugs.

======================================

All IMHO.

On the Dual analysis side (Molecular) now Illumina have taken an interest, including working with angle for 6 months to perfect the lung cancer assay panel:-

"Illumina’s cell-free DNA prep with enrichment and a custom 79-gene panel targeting lung cancer". We await news on the next ones.

Current vacancies from their web site:-

Scientist I Molecular

Phlebotomist

Ledger Assistant

Laboratory Technician PTD

HR Advisor

Senior Clinical Scientist – Molecular

Clinical Scientist Imaging

Manufacturing Senior Manager

https://angleplc.com/about-us/careers/

https://angleplc.com/laboratory-services/

Will be rolled out throughout NHS England? Worth pointing out that NHS Scotland have decided to implement already, and that NHS England/NICE are dragging their heels with the long-term test which in my opinion at least is unnecessary now the machine has been on test for many months already at 9 hospitals. All this time they risk another baby losing it's hearing with the massive cost of supporting it through the rest of its life. How many £ millions is that?

https://www.genedrive.com/assays/rnr1-product.php

All IMHO..

Down 5.5%?

Will be rolled out throughout NHS England? Worth pointing out that NHS Scotland have decided to implement already, and that NHS England/NICE are dragging their heels with the long-term test which in my opinion at least is unnecessary now the machine has been on test for many months already at 9 hospitals. All this time they risk another baby losing it's hearing with the massive cost of supporting it through the rest of its life. How many £ millions is that?

https://www.genedrive.com/assays/rnr1-product.php

All IMHO.

Https://www.linkedin.com/posts/genedrive-plc_gdr-poct-pointofcare-activity-7326610597645611011-RP-V

And this video!

https://www.hiss-dx.de/en-DE/Partner/Angle/

Https://www.hiss-dx.de/en-DE/products/area-of-interest/molecular-biology-cell-culture/instruments/

Here:-

https://ismrc-symposium.eu/

Used to guide treatment decisions when a tissue sample is unavailable. So, analysing a standard blood sample (liquid biopsy) is already used. Fact. LabCorp do what is called CtDna analysis. This stands for circulating tumour DNA analysis. However, this standard approach only looks at fragments of shed DNA which are present in everyone's blood whether they have cancer or not. If you have cancer some DNA "biomarkers" can sometimes be found indicating cancer. If you have cancer and certain specific biomarkers are found that can mean your cancer is suitable for cancer treatments which can home in on the biomarkers thus targeting the cancer directly. If the specific biomarkers are not found targeted treatment is deemed not suitable. What Angle Plc have discovered is analysing the same blood sample's circulating tumour cells (CTC's) at the same time as the DNA fragments results in about twice the number of biomarkers being found. Therefore, the persons chances of being suitable for targeted cancer treatment is about doubled.

Apart from Illumina the market seems asleep to this even though independent labs have confirmed Angle's findings first announced in the RNS dated 4th Jan 2024.

Meanwhile Angle Plc is moving forward with Illumina to productise the assay panel for lung cancer which is already advertised on Angle Plc's web site. They will follow on with ones for Breast cancer etc...

Angle also offer a "pan cancer" analysis using the NuProbe assay panel. This panel was used to produce the results for the RNS dated 4th Jan 2024.

The market is totally asleep to this. It will wake up at some point.

All IMHO.

Interesting on their site the video about liquid biopsy. Shows liquid biopsies are already used to guide treatment when a solid tissue sample is unobtainable. Also shows how CtDna analysis of blood is already used to guide treatment decisions by finding cancer DNA that is targetable by some modern drugs. This explains why the A.I. has suggested LabCorp might be looking to use Angle's Parsortix so they can add dual analysis to their service. This would double the chances of finding cancer DNA that is targetable by some modern drugs.

All IMHO.